A strong positioning point of the patent is the¬†protection for all future applications and products under the buoyant separation protocols in the pipeline. These include Akadeum‚Äôs upcoming leukopaks isolation and dead cell removal kits, the company noted.¬†The patent also strengthens Akadeum’s position to license its technology for broader use in ongoing cell and gene-based therapy research in many areas, such as immuno-oncology.

‚ÄúFrom day one, our mission has been to solve today‚Äôs problems facing researchers and scientists in the field of cell separation,‚ÄĚ said Brandon McNaughton, PhD, CEO and founder of Akadeum.¬†‚ÄúThe issuance of this patent stems from the origins of Akadeum‚Äôs body of work and cements our position as the leading company offering solutions in flotation-based cell separation technologies.¬†More importantly, this patent strengthens the ability for Akadeum to provide proprietary products that support groundbreaking biological and clinical discoveries of researchers.‚ÄĚ

Read more here.